創薬におけるAI：世界市場

世界の創薬におけるAIの市場規模は、2023年の16億米ドルから、予測期間中は29.6％のCAGRで推移し、2028年には57億米ドルの規模に成長すると予測されています。

用途別で見ると、前臨床試験の部門が2023年の3億930万米ドルから、39.2%のCAGRで推移し、2028年には16億米ドルの規模に成長すると予測されています。また、標的同定の部門が2023年の3億6,270万米ドルから、33.2％のCAGRで推移し、2028年には15億米ドルの規模に成長すると予測されています。

当レポートでは、世界の創薬におけるAIの市場を調査し、市場概要、市場影響因子および市場機会の分析、市場規模の推移・予測、各種区分・地域別の詳細分析、ESGの展開、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 サマリー・ハイライト

第3章 市場概要

• 将来の展望

第4章 市場力学

• 市場促進要因
• 世界的な慢性疾患と感染症の有病率の上昇
• 製薬分野でのAI採用の増加
• 製薬分野におけるAIの可能性
• 市場抑制要因
• 創薬におけるAIの課題
• 市場機会
• 部門間の提携・合併

第5章 規制状況・償還シナリオ

• 規制状況
• 北米
• 欧州
• アジア太平洋

第6章 COVID-19による市場への影響

• 概要
• COVID-19による危機
• AIを活用したCOVID-19の創薬とワクチン開発
• COVID-19が創薬におけるAIに与える影響
• COVID-19対策

第7章 市場内訳：用途別

• 前臨床試験
• 標的同定
• 候補薬のスクリーニング・リードの最適化
• ドラッグリポジショニング
• De Novo薬剤設計
• その他

第8章 市場内訳：治療領域別

• 腫瘍
• 感染症
• 神経変性疾患
• 心血管疾患
• 代謝性疾患
• その他

第9章 市場内訳：地域別

• 概要
• 北米
• 欧州
• アジア太平洋
• その他の地域

第10章 ESGの展開

• ESGの導入
• 環境
• 社会
• 政府
• 創薬業界におけるAIサプライヤーの持続可能性
• AI業界における製薬エンドユーザーの持続可能性
• ケーススタディ
• BCCによる総論

第11章 新たな技術と開発

• 概要
• 現在の市場動向
• 新興技術
• セルペインティング
• 量子コンピューティング
• メタボロミクス

第12章 M&Aと資金調達の見通し

• M&A分析
• 主な戦略的提携

第13章 競合情勢

• 競合分析
• AIのビジョンと戦略
• 技術とデータ
• 外部AIコラボレーション
• 社内の人材管理
• 文化と仕事の方法
• 企業シェア分析

第14章 企業プロファイル

• ARIA PHARMACEUTICALS INC.
• ATOMWISE INC.
• BENEVOLENTAI
• EXSCIENTIA PLC
• INSILICO MEDICINE
• RECURSION PHARMACEUTICALS INC.
• RELAY THERAPEUTICS INC.
• SCHRODINGER INC.
• XTALPI INC.

第15章 付録：頭字語

List of Tables

• Summary Table : Global Market for AI in Drug Discovery, by Application, Through 2028
• Table 1 : Global Totals of Angina Pectoris and Stroke Survivors, Through 2030
• Table 2 : Global Incidence and Prevalence of All Stroke Types, 2019
• Table 3 : Global Prevalence of Congestive Heart Failure and Stroke, Through 2030
• Table 4 : Global Diabetes Prevalence, Estimates and Projections, 2019-2045
• Table 5 : Cases of Diabetes Worldwide, by Type, 2019
• Table 6 : Global Prevalence of Diabetes, by Type, Through 2040
• Table 7 : Global Prevalence of Breast Cancer Cases, by Country/Region, Through 2025
• Table 8 : Global Epidemiology of Colorectal Cancer, by Region, Through 2030
• Table 9 : Global Occurrences of Deaths, by Various Cancer Types, Through 2030
• Table 10 : Breakdown of Global Deaths Due to Cancer, by Various Cancer Types, 2021
• Table 11 : Prevalence of Multiple Sclerosis, by Region, 2013 and 2020
• Table 12 : Global Prevalence of Symptomatic Key Musculoskeletal Disorders, Through 2025
• Table 13 : Global Occurrences of Deaths, by Various Musculoskeletal Disorders, Through 2030
• Table 14 : Global Occurrences of Deaths from Digestive Diseases, by Region, Through 2025
• Table 15 : Global HIV Epidemic, by Age Group, 2020
• Table 16 : Global Market for AI in Drug Discovery, by Application, Through 2028
• Table 17 : Global Market for AI in Preclinical Testing Application, by Region, Through 2028
• Table 18 : Global Market for AI in Target Identification Application, by Region, Through 2028
• Table 19 : Global Market for AI in Candidate Screening and Lead Optimization Application, by Region, Through 2028
• Table 20 : Global Market for AI in Drug Repurposing Application, by Region, Through 2028
• Table 21 : Global Market for AI in De Novo Drug Design Application, by Region, Through 2028
• Table 22 : Global Market for AI in Other Drug Discovery Applications, by Region, Through 2028
• Table 23 : Global Market for AI in Drug Discovery, by Therapeutic Area, Through 2028
• Table 24 : Global Market for AI in Drug Discovery for Oncology, by Region, Through 2028
• Table 25 : Global Market for AI in Drug Discovery in Infectious Diseases, by Region, Through 2028
• Table 26 : Global Market for AI in Drug Discovery in Neurodegenerative Diseases, by Region, Through 2028
• Table 27 : Global Market AI in Drug Discovery in Cardiovascular Diseases, by Region, Through 2028
• Table 28 : Share of Global Diabetes Cases, by Type
• Table 29 : Global Market for AI in Drug Discovery in Metabolic Diseases, by Region, Through 2028
• Table 30 : Global Market for AI in Drug Discovery in Other Diseases, by Region, Through 2028
• Table 31 : Global Market for AI in Drug Discovery, by Region, Through 2028
• Table 32 : Diabetes Estimates in North America, by Country, 2000-2045
• Table 33 : Influenza Disease Burden in the U.S., by Age Group, 2019-2020 Influenza Season
• Table 34 : North American Market for AI in Drug Discovery, by Country, Through 2028
• Table 35 : Diabetes Estimates in Europe, by Country, 2000-2045
• Table 36 : European Market for AI in Drug Discovery, by Country, Through 2028
• Table 37 : Tuberculosis Burden of Asian Countries, by Country, 2019
• Table 38 : Diabetes Estimates for the Asia-Pacific Region, by Country, 2000-2045
• Table 39 : Asia-Pacific Market for AI in Drug Discovery, by Country, Through 2028
• Table 40 : Diabetes Estimates in the RoW, by Country, 2000-2045
• Table 41 : Estimation of New Cancer Cases in Africa, by Cancer Type, 2020 and 2024
• Table 42 : Rest of the World Market for AI in Drug Discovery, by Sub-region, Through 2028
• Table 43 : Key Focus Areas in ESG Metrics
• Table 44 : ESG Rankings for Few AI Companies for Drug Discovery, 2023
• Table 45 : ESG Rankings for Major Pharma Companies Utilizing AI for Drug Discovery, 2023
• Table 46 : Major Strategic Alliances, AI in Drug Discovery Market, 2018-2023
• Table 47 : Aria Pharmaceuticals: Pipeline Products
• Table 48 : Aria Pharmaceuticals: AI Offerings
• Table 49 : Atomwise: Pipeline Products
• Table 50 : Atomwise: AI Offerings
• Table 51 : Atomwise: News/Developments, 2019-2022
• Table 52 : BenevolentAI: Pipeline Products
• Table 53 : BenevolentAI: AI Offerings
• Table 54 : BenevolentAI: Annual Revenue, 2022
• Table 55 : Benevolent AI: News/Developments, 2019-2023
• Table 56 : Exscientia Plc: Pipeline Products
• Table 57 : Exscientia Plc: AI Offerings
• Table 58 : Exscientia Plc: Annual Revenue, 2022
• Table 59 : Exscientia Plc: News/Developments, 2021-2022
• Table 60 : Insilico Medicine: Pipeline Products
• Table 61 : Insilico Medicine: AI Offerings
• Table 62 : Insilico Medicine: News/Developments, 2021-2023
• Table 63 : Recursion: Pipeline Products
• Table 64 : Recursion: AI Offerings
• Table 65 : Recursion: Annual Revenue, 2022
• Table 66 : Recursion: News/Developments, 2021-2023
• Table 67 : Relay Therapeutics: Pipeline Products
• Table 68 : Relay Therapeutics: AI Offerings
• Table 69 : Relay Therapeutics: Annual Revenue, 2022
• Table 70 : Relay Therapeutics: News/Developments, 2019-2022
• Table 71 : Schrodinger: Pipeline Products
• Table 72 : Schrodinger: Pipeline Products - II Collaborative Programs
• Table 73 : Schrodinger: AI Offerings
• Table 74 : Schrodinger: Annual Revenue, 2022
• Table 75 : Schrodinger: News/Developments, 2020-2022
• Table 76 : XtalPi: AI Offerings
• Table 77 : XtalPi: News/Developments, 2021-2023
• Table 78 : Acronyms Used in This Report

List of Figures

• Summary Figure : Global Market Shares of AI in Drug Discovery, by Application, 2022
• Figure 1 : Traditional vs. AI-Based Drug Delivery Techniques
• Figure 2 : Timeline of AI in Drug Discovery Industry
• Figure 3 : Growth of AI in Drug Discovery in Initial Phases, 2013-2021
• Figure 4 : Breakdown of Worldwide Diabetes Cases, by Type, 2019
• Figure 5 : Global Prevalence of Diabetes, by Type, 2018 and 2040
• Figure 6 : Breakdown of New Cancer Cases in Women, by Cancer Type, 2020
• Figure 7 : Breakdown of New Cancer Cases in Men, by Cancer Type, 2020
• Figure 8 : Global Prevalence of Breast Cancer Cases, by Country/Region, 2015-2025
• Figure 9 : Global Epidemiology of Colorectal Cancer, by Region, 2000-2030
• Figure 10 : Global Occurrences of Deaths, by Various Cancer Types, 2000-2030
• Figure 11 : Breakdown of Global Deaths Due to Cancer, by Various Cancer Types, 2021
• Figure 12 : Global Prevalence of Symptomatic Key Musculoskeletal Disorders, by Region, 2018
• Figure 13 : Breakdown of Global Occurrences of Deaths, by Various Musculoskeletal Disorders, 2015
• Figure 14 : Global Occurrences of Deaths from Digestive Diseases, by Region, 2015-2025
• Figure 15 : Top Pharma Companies AI Deals, by Company, 2020
• Figure 16 : Top AI and Tech Partners and Pharma Deals, by Company, 2020
• Figure 17 : Applications of AI in Drug Discovery
• Figure 18 : Global Market for AI in Preclinical Testing Application, 2020-2028
• Figure 19 : Global Market for AI in Target Identification Application, 2020-2028
• Figure 20 : Global Market for AI in Candidate Screening and Lead Optimization Application, 2020-2028
• Figure 21 : Drug Repurposing Approaches
• Figure 22 : Global Market for AI in Drug Repurposing Application, 2020-2028
• Figure 23 : Global Market for AI in De Novo Drug Design Application, 2020-2028
• Figure 24 : Global Market for AI in Other Drug Discovery Applications, 2020-2028
• Figure 25 : Global Market for AI in Drug Discovery for Oncology, 2020-2028
• Figure 26 : Global Market for AI in Drug Discovery in Infectious Diseases, 2020-2028
• Figure 27 : Global Market for AI in Drug Discovery in Neurodegenerative Diseases, 2020-2028
• Figure 28 : Global Market for AI in Drug Discovery in Cardiovascular Diseases, 2020-2028
• Figure 29 : Share of Global Diabetes Cases, by Type
• Figure 30 : Global Market for AI in Drug Discovery in Metabolic Diseases, 2020-2028
• Figure 31 : Global Market for AI in Drug Discovery in Other Diseases, 2020-2028
• Figure 32 : Global Market Shares of AI in Drug Discovery, by Region, 2022
• Figure 33 : North American Market for AI in Drug Discovery, by Country, 2020-2028
• Figure 34 : Share of Cancer Diagnosis in Europe, by Gender, 2020
• Figure 35 : European Market for AI in Drug Discovery, by Country, 2020-2028
• Figure 36 : Asia-Pacific Market for AI in Drug Discovery, by Country, 2020-2028
• Figure 37 : Rest of the World Market for AI in Drug Discovery, by Sub-region, 2020-2028
• Figure 38 : How a Strong ESG Proposition Benefits Businesses
• Figure 39 : ESG-Adoption Level Across All the Industries, Global, 2021 and 2022
• Figure 40 : The Ten Business Sustainability Trends Identified for 2022
• Figure 41 : Key Sustainable Practices Being Implemented in Research Laboratories
• Figure 42 : ESG Commitments of Recursion
• Figure 43 : Emerging Technologies in the AI in Drug Discovery Market
• Figure 44 : Venture Capital Deals Including Corporate Pharma and Biotech Investors, by Year, 2013-2022
• Figure 45 : Investments in the AI in Drug Discovery Industry, by Year, 2014-2020
• Figure 46 : Shares of Global Market for AI in Drug Discovery, by Company, 2022
• Figure 47 : BenevolentAI: Annual Revenue, 2021 and 2022
• Figure 48 : Exscientia Plc: Annual Revenue, 2021 and 2022
• Figure 49 : Exscientia Plc: Revenue Share, by Country/Region, 2022
• Figure 50 : Recursion: Annual Revenue, 2021 and 2022
• Figure 51 : Relay Therapeutics: Annual Revenue, 2021 and 2022
• Figure 52 : Schrodinger: Annual Revenue, 2021 and 2022
• Figure 53 : Schrodinger: Revenue Share, by Segment, 2022
• Figure 54 : Schrodinger: Revenue Share, by Region/Country, 2022

Highlights:

The global market for artificial intelligence (AI) in drug discovery is estimated to increase from $1.6 billion in 2023 to $5.7 billion by 2028, at a compound annual growth rate (CAGR) of 29.6% from 2023 through 2028.

The global market for AI in preclinical testing application is estimated to increase from $309.3 million in 2023 to $1.6 billion by 2028, at a CAGR of 39.2% from 2023 through 2028.

The global market for AI in target identification application is estimated to increase from $362.7 million in 2023 to $1.5 billion by 2028, at a CAGR of 33.2% from 2023 through 2028.

Report Scope:

The current report will provide a detailed overview of the AI in the drug discovery market. This report analyzes the market trends associated with AI in drug discovery using data from 2020, estimates from 2021, projections of compound annual growth rates through 2028 (i.e., the forecast period 2023-2028), and information about regional markets of AI in drug discovery. This report will highlight the current and future market potential of AI in drug discovery and provide a detailed analysis of the competitive environment. It will cover regulatory scenarios, drivers, restraints and opportunities as well as market projections for 2028 and the market shares held by key market players.

The scope of the market in this report is segmented into applications, therapeutic areas and region. The applications of AI in drug discovery are further segmented into preclinical testing, target identification, candidate screening and lead optimization, drug repurposing, De novo Drug Design and others. The AI in drug discovery market is segmented by therapeutic area into the following segments: oncology, neurodegenerative diseases, cardiovascular diseases, metabolic diseases, infectious diseases, and others. This report includes a regional market analysis of AI in drug discovery. The market has been segmented by region into various significant geographies: North America, Europe, Asia-Pacific, and the Rest of the World regions. Detailed analysis of major countries such as the U.S., Germany, the U.K., Italy, France, Japan, China and India will be covered within the chapter focused on regional segmentation. For market estimates, 2022 serves the base year; forecasts are given from 2023-2028.

The regional market analysis of AI in drug discovery is also covered in this report. The market has been segmented into various significant geographies, including North America, Europe, Asia-Pacific, and other world regions. Detailed analysis of major countries such as the U.S., Germany, the U.K., Italy, France, Japan, China, and India will be covered within the regional segment. For market estimates, data will be provided for 2022 because of the base year, with estimates for 2023 and forecast value for 2028.

Report Includes:

• 49 data tables and 30 additional tables
• An up-to-date overview and industry analysis of the global markets for artificial intelligence (AI) in drug discovery
• Analyses of the global market trends, with historical market revenue data (sales figures) from 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
• Estimation of the actual market size and revenue forecast for the AI in drug discovery market, and corresponding market share analysis based on application, therapeutic area, and region
• In-depth information (facts and figures) concerning the major factors influencing the progress of this market (drivers, restraints, opportunities, and industry-specific challenges) with respect to specific growth trends, upcoming prospects, and contributions to the overall market
• Understanding of the importance of ESG in the AI in drug discovery market, consumer attitudes, risks and opportunity assessment, and ESG followed practices by top vendor companies
• Discussion of emerging technologies and new developments in the AI in drug discovery market
• Identification of the major and emerging players who are considered as leaders in the AI in drug discovery market, as well as technological means these companies are using to exploit their markets and dominate the market in their fields
• Review of the structure of this industry with respect to company market shares, venture fundings, and recent merger and acquisition (M&A) activities
• Analysis of their company competitive landscape based on recent developments, key financials and segmental revenues, and operational integration
• Detailed company profiles of the leading market players, including Atomwise Inc., BenevolentAI, Insilico Medicine, Exscientia plc, Recursion Pharmaceuticals Inc., and Schrodinger

Table of Contents

Chapter 1 Introduction

• Overview
• Artificial Intelligence
• Drug Discovery
• Artificial Intelligence in Drug Discovery
• Study Goals and Objectives
• Reasons for Doing This Study
• Scope of Report
• Methodology
• Information Sources
• Geographic Breakdown

Chapter 2 Summary and Highlights

• Market Outlook
• Market Insights

Chapter 3 Market Overview

• Introduction
• Future Perspectives

Chapter 4 Market Dynamics

• Market Drivers
• Rising Prevalence of Chronic and Infectious Diseases Globally
• Increasing Adoption of AI in Pharmaceutical Sector
• Potential of AI in Pharma Sector
• Market Restraints
• Challenges with AI in Drug Discovery
• Market Opportunities
• Partnerships and Mergers Between Sectors

Chapter 5 Regulatory Landscape and Reimbursement Scenario

• Regulatory Landscape
• North America
• Europe
• Asia-Pacific

Chapter 6 Impact of COVID-19 on Market

• Overview
• COVID-19 Crisis
• COVID-19 Drug Discovery and Vaccine Development Using AI
• Impact of COVID-19 on AI in Drug Discovery
• COVID-19 Measures

Chapter 7 Market Breakdown by Application

• Applications of AI in Drug Discovery
• Preclinical Testing
• Target Identification
• Candidate Screening and Lead Optimization
• Drug Repurposing
• De Novo Drug Design
• Other Applications

Chapter 8 Market Breakdown by Therapeutic Area

• AI in Drug Discovery by Therapeutic Area
• Oncology
• Infectious Diseases
• Neurodegenerative Diseases
• Cardiovascular Diseases
• Metabolic Diseases
• Other Diseases

Chapter 9 Market Breakdown by Region

• Overview
• North America
• U.S. Market Size and Forecast
• Canadian Market Size and Forecast
• Europe
• German Market Size and Forecast
• U.K. Market Size and Forecast
• French Market Size and Forecast
• Italian Market Size and Forecast
• Spanish Market Size and Forecast
• Rest of European Market Size and Forecast
• Asia-Pacific
• Chinese Market Size and Forecast
• Japanese Market Size and Forecast
• Indian Market Size and Forecast
• South Korean Market Size and Forecast
• Rest of Asia-Pacific Market Size and Forecast
• Rest of the World
• South American Market Size and Forecast
• Middle East and African Market Size and Forecast

Chapter 10 ESG Development

• Introduction to ESG
• Environmental
• Social
• Government
• The Sustainability of AI Suppliers in Drug Discovery Industry
• Pharma End User Sustainability in the AI Industry
• Case Study
• Concluding Remarks from BCC

Chapter 11 Emerging Technologies and Developments

• Overview
• Current Market Trends
• Emerging Technologies
• Cell Painting
• Quantum Computing
• Metabolomics

Chapter 12 M&A and Funding Outlook

• M&A Analysis
• Major Strategic Alliances

Chapter 13 Competitive Landscape

• Competitive Analysis
• Vision and Strategy for AI
• Technology and Data
• External AI Collaborations
• Managing Internal Talent
• Culture and Methods of Work
• Company Share Analysis

Chapter 14 Company Profiles

• ARIA PHARMACEUTICALS INC.
• ATOMWISE INC.
• BENEVOLENTAI
• EXSCIENTIA PLC
• INSILICO MEDICINE
• RECURSION PHARMACEUTICALS INC.
• RELAY THERAPEUTICS INC.
• SCHRODINGER INC.
• XTALPI INC.

Chapter 15 Appendix: Acronyms